These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30952575)

  • 1. Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population.
    Bonadonna RC; Giaccari A; Buzzetti R; Aimaretti G; Cucinotta D; Avogaro A; Perseghin G; Larosa M; Bolli GB; Fanelli CG
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):496-503. PubMed ID: 30952575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
    Bonadonna RC; Giaccari A; Buzzetti R; Perseghin G; Cucinotta D; Avogaro A; Aimaretti G; Larosa M; Fanelli CG; Bolli GB
    Diabetes Metab Res Rev; 2020 Sep; 36(6):e3304. PubMed ID: 32118347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [No Abstract]   [Full Text] [Related]  

  • 4. Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.
    Giaccari A; Bonadonna RC; Buzzetti R; Perseghin G; Cucinotta D; Fanelli C; Avogaro A; Aimaretti G; Larosa M; Pagano V; Bolli GB
    Acta Diabetol; 2021 Jun; 58(6):789-796. PubMed ID: 33586058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes.
    Russell-Jones D; Dauchy A; Delgado E; Dimitriadis G; Frandsen HA; Popescu L; Schultes B; Strojek K; Bonnemaire M; Roborel de Climens A; Davies M
    Diabetes Obes Metab; 2019 Jul; 21(7):1615-1624. PubMed ID: 30851006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects.
    Sieber J; Weinheimer M; Kongable G; Riddle S; Chang YY; Flacke F
    J Diabetes Sci Technol; 2020 Sep; 14(5):898-907. PubMed ID: 31288531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
    Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
    Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1846-1853. PubMed ID: 38693036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
    Hong EG; Min KW; Lim JS; Ahn KJ; Ahn CW; Yu JM; Kim HS; Kim HJ; Kim W; Kim DH; Jang HC
    Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
    Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
    Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
    Freemantle N; Mauricio D; Giaccari A; Bailey T; Roussel R; Franco D; Berthou B; Pilorget V; Westerbacka J; Bosnyak Z; Bonnemaire M; Cali AMG; Nguyên-Pascal ML; Penfornis A; Perez-Maraver M; Seufert J; Sullivan SD; Wilding J; Wysham C; Davies M
    Curr Med Res Opin; 2020 Apr; 36(4):571-581. PubMed ID: 31865758
    [No Abstract]   [Full Text] [Related]  

  • 15. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
    Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study.
    Li X; Du T; Li W; Zhang T; Liu H; Xiong Y
    Clin Ther; 2014 Sep; 36(9):1269-75. PubMed ID: 25062651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
    Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
    Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs.
    Seufert J; Fritsche A; Pscherer S; Anderten H; Borck A; Pegelow K; Bramlage P; Pfohl M
    Diabetes Obes Metab; 2019 Feb; 21(2):439-443. PubMed ID: 30226296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial.
    Harris SB; Yale JF; Berard L; Stewart J; Abbaszadeh B; Webster-Bogaert S; Gerstein HC
    Diabetes Care; 2014; 37(3):604-10. PubMed ID: 24170757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.